32 min listen
Precision Pioneers EP 5: Alnylam's Josh Friedman on developing precision medicines for the 'silent killer' NASH/NAFLD
Precision Pioneers EP 5: Alnylam's Josh Friedman on developing precision medicines for the 'silent killer' NASH/NAFLD
ratings:
Length:
34 minutes
Released:
May 5, 2021
Format:
Podcast episode
Description
On this episode of the podcast, Patrick is joined by Josh Friedman, Senior Director of Research at Alnylam Pharmaceuticals. Alnylam works on the discovery and development of RNA interference therapeutics; treatments for genetic diseases which work by ‘switching off’ the specific genes associated with a given condition. In this fifth episode of our precision pioneers miniseries, we explore how RNA interference can be applied to treat common and rare genetic diseases, and dive deep into the genetics of non-alcoholic fatty liver disease and NASH.
Released:
May 5, 2021
Format:
Podcast episode
Titles in the series (100)
EP 2 What One Man Learnt From Over 300 DNA Tests: Is Craig one of the most thoroughly DNA tested people on the planet? Quite possibly, but one thing's for sure, his company (dnatestingchoice.com) know a thing or two about a good DNA test. This fascinating discussion with Craig Macpherson explores the... by The Genetics Podcast